icon star paper   News Update  
Back grey_arrow_rt.gif
The Immune Response Corp Presents New Phase II Clinical Data Indicating That REMUNE Induces A HIV-Specific Immune Response
September 14, 2004 10:35 a.m.
CARLSBAD, Calif. -- Interim results of a phase II study indicate Immune Response Corp.'s (IMNR) Remune induces HIV-specific immunity in patients who have the virus but have never been treated.
The company said results from the interim analysis of the single-blind, randomized study suggested that Remune can produce positive clinical results.
In a press release Tuesday, Immune Response said the investigational treatment was reviewed in an ongoing multi-center study conducted in Italy.
Immune Response said the results from this trial, which investigated 50 subjects over 28 weeks, will be rolled over into its ongoing clinical trial investigating IR103, which combines Remune with Amplivax.
Amplivax, an immunostimulatory oligonucleotide adjuvant, was licensed from Hybridon Inc. (HBY).
Remune has not been approved by any regulatory agencies in any country at this time.
The biopharmaceutical company is developing immune-based therapies for HIV and multiple sclerosis.
  icon paper stack View Older Articles   Back to Top   www.natap.org